TCRVβ-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers.

We tested primary malignant cells from other patients with TCR Vβ2 + PBMCs and found that anti-TCR Vβ2-PNU was highly significant in inducing malignant cell death compared to an unconjugated anti-TCR Vβ2 antibody ( Figure 2 E-F).

also in 132,142 other papers